MBio Diagnostics, Inc. is a clinical diagnostics and life sciences technology company developing a suite of simple, multiplexed diagnostic tests using its proprietary LightDeckTM technology. Initial product development had focused on high impact infectious diseases to include HIV, hepatitis, and influenza. The companys product development had aimed at decentralized testing, from the clinic to the home. To that end, the firm has develops a suite of multiplexed diagnostic tests with products now including CD4 System, which provides CD4 T helper cell counts at the point-of care; and MBio Array, a multiplexed fluorescence immunoassay system that provides the simultaneous measurement of multiple analytes from a sample. The company products are based on LightDeck, a fluorescence assay illumination method and variation on planar waveguide technology used for performing sensitive biological assays enabling expansion to rapid CD4 cell counting, and hepatitis and syphilis co-infection testing applications.